$200 for 5ml
Latisse is the only FDA-approved treatment clinically proven to grow lashes.
Frequently Asked Questions
Latisse contains the active ingredient Bimatoprost which increases the length and number of hairs in the growth phase.
The active ingrediants are believed to affect the growth (anagen) phase of the eyelash hair cycle in two ways: it increases the length of this phase and it increases the number of hairs in this growth phase.
Increasing the number of eyelashes
Just a few minutes. This is a once-a-day treatment, you apply Latisse topically to the base of your upper eyelashes each night, or as instructed by your doctor. t.
You may start seeing results in as little as 4 weeks and should achieve full growth in 16 weeks.
Once you begin, you must continue applying the topical solution each night. If you stop using Latisse at any time, your eyelashes will return to their previous appearance over several weeks to months.
Side effects are possible, here’s what to look out for:
- Itching sensation in the eyes
- Eye redness
- Eyelid skin darkening (less common)
- Eye irritation (less common)
- Dryness of the eyes
- Redness of the eyelids (less common)
If you’re using Latisse and you develop a new ocular condition or reaction (e.g., trauma or infection), experience a sudden decrease in visual acuity, or need to have eye surgery, be sure to talk to your doctor immediately concerning the continued use.
Apply to clean eyes.
When you stop using Latiesse, your eyelashes will return to their previous appearance.
LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information
LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
Important Safety Information
Contraindications: LATISSE® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients.
Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. LATISSE® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Adverse Reactions: The most frequently reported adverse reactions were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and periorbital erythema. These reactions occurred in less than 4% of patients.
Postmarketing Experience: The following adverse reactions have been identified during postapproval use of LATISSE®: dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), and vision blurred.
Please see LATISSE® full Prescribing Information.